SPONSORED CONTENT
Saving people’s lives.
Eliminating the stigma surrounding a host of physical and mental health conditions.
Advocating for the health equity of underserved populations.
Executing targeted marketing campaigns.
One of these initiatives indeed feels less service-oriented than the others. But once you kick all
…
SPONSORED CONTENT
In 1999, the Centers for Disease Control and Prevention (CDC) launched the National Campaign to Eliminate Syphilis from the United States. The CDC updated its ambitious plan in 2006 and aimed to reduce rates of primary and secondary
…
SPONSORED CONTENT
TIP: For sites submitting data to 340B ESP, the option exists within the 340B ESP portal to “Attest” for several manufacturers which will
SPONSORED CONTENT
With new leadership in Congress, the drumbeat for greater scrutiny of 340B will grow. To date, news outlets from The New York Times to The Wall Street Journal have quoted former government
…
SPONSORED CONTENT
It’s that time again: The 340B Coalition Winter Conference, known as the can’t-miss gathering of covered entities, health care providers, pharmacy and pharmacy service providers, drug manufacturers, government agencies, and other organizations dedicated to driving health
…
SPONSORED CONTENT
TIP: Accurately tracking and loading drug prices into the ESP system can be the difference maker when it comes to maintaining compliance and
I was born and raised in Chicago, IL and later moved to Elmhurst, IL. I’ve lived in Illinois my entire life.
Read More »SPONSORED CONTENT
Will you be attending the 340B Winter Coalition Conference in San Diego? Start your week with the latest developments in the 340B program. This year, Verity Solutions will be hosting a panel
…
In the episode “340B Insights: The Current State of the 340B Program,” RxStrategies’ Jonathan Ghenn and Rhodie Smith connect with Ted Slafsky, Publisher and CEO of the 340B Report to share information on what’s important to Covered Entities and pharmacy professionals who manage a 340B Program
…
SPONSORED CONTENT
This past November, the 340B program celebrated its 30th anniversary—a huge milestone and a reason to rejoice and reflect. We are dismayed, however, that certain drug manufacturers are trying to revise the 340B program’s past and reimagine its future. More than 20 drug manufacturers have unilaterally and unlawfully
…*Sign up for news summaries and alerts from 340B Report
